KBC Group’s Bioverativ Inc. Common Stock BIVV Stock Holding History

KBC Group’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11,429	Closed	-$617K	–	1340
2017 Q4	$617K	Sell	11,429 -6,022	-35%	-$329K	0.01%	923
2017 Q3	$996K	Sell	17,451 -6,786	-28%	-$397K	0.01%	803
2017 Q2	$1.46M	Sell	24,237 -35,068	-59%	-$2M	0.01%	660
2017 Q1	$3.23M	Buy	+59,305	New	+$2.92M	0.03%	522

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

KBC Group's BIVV Position: Q1 2018 in Review

KBC Group sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 11,429 shares — an estimated $617K sold.

KBC Group first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $3.23M in Q1 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

KBC Group reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
KBC Group sold 11,429 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $617K.
KBC Group first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
KBC Group's Bioverativ Inc. Common Stock position peaked at $3.23M in Q1 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on KBC Group's 13F filing for Q1 2018, filed 9 May 2018.